Literature DB >> 695698

Metabolic fate of 1-hexylcarbamoyl-5-fluorouracil in rats.

T Kobari, K Tan, M Kumakura, S Watanabe, I Shirakawa, H Kobayashi, A Ujiie, Y Miyama, H Namekawa, H Yamamoto.   

Abstract

1. The metabolic fate of a new antitumour agent, 1-hexylcarbamoyl-5-fluoro [6-14C]uracil (14C-HCFU) in rats after oral administration was compared with that of 5-fluoro[6-14C]uracil (14C-FU). 2. Tissue radioactivity reached a max. 1 to 3 h after administration of 14C-HCFU and 0.5 h after 14C-FU. 3. Both drugs were excreted rapidly, mostly in urine. Expired 14CO2 from 14C-HCFU was significantly less than that from 14C-FU. 4. Unchanged FU was not detected in plasma 3 h after administration of 14C-FU, whereas FU was detected in plasma 5 h after 14C-HCFU. The pyrimidine ring of 14C-HCFU might be degradated more slowly than that of 14C-FU. 5. 1-(5-Carboxypentylcarbamoyl)-5-fluorouracil and 1-(3-carboxypropylcarbamoyl)-5-fluorouracil were identified as the major urinary metabolites of 14C-HCFU.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 695698     DOI: 10.3109/00498257809061254

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  3 in total

1.  Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs.

Authors:  R Okeda; T Karakama; S Kimura; S Toizumi; T Mitsushima; Y Yokoyama
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

Review 2.  Subacute leucoencephalopathy induced by carmofur, a 5-fluorouracil derivative.

Authors:  S Kuzuhara; N Ohkoshi; K Kanemaru; H Hashimoto; T Nakanishi; Y Toyokura
Journal:  J Neurol       Date:  1987-08       Impact factor: 4.849

3.  Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity.

Authors:  Natalia Realini; Carlos Solorzano; Chiara Pagliuca; Daniela Pizzirani; Andrea Armirotti; Rosaria Luciani; Maria Paola Costi; Tiziano Bandiera; Daniele Piomelli
Journal:  Sci Rep       Date:  2013-01-08       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.